ArticleJournal of research in pharmacy practice2026
Systematic Review of Bortezomib-based Desensitization Therapy in Sensitized Kidney Transplant Candidates: Efficacy, Safety, and Clinical Outcomes.
Article in Journal of research in pharmacy practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Highly sensitized kidney transplant candidates, those with high levels of antihuman leukocyte antigens antibodies, are at increased risk of antibody-mediated graft rejection. The goal of desensitization therapy is to reduce alloantibody titers and increase the chance and success of transplantation. The proteasome inhibitor bortezomib, which acts against plasma cells, has been reported to be an effective agent in this setting. This systematic review evaluates the efficacy and safety of bortezomib-based desensitization regimens in sensitized kidney transplant recipients. Methods: A systematic search of various databases was conducted between January 2005 and July 2025. Studies that considered sensitized kidney transplant candidates treated with bortezomib-based desensitization were included, and outcomes included reduction in donor-specific antibodies (DSA), engraftment rate, graft rejection, and adverse events. Findings: A total of 21 studies involving about 185 patients were included, comprising 11 case reports, 6 case series, and 4 clinical trials or prospective studies. Overall graft success rate was 87% rejection-free outcomes 76% and no more adverse events in 81%. While most studies showed significant DSA reduction, one reported limited effectiveness. Bortezomib was generally well-tolerated, with no major adverse events in approximately 81% of studies. Mild neuropathy was noted in some cases, and treatment discontinuation occurred in 20% of patients in one trial. Conclusion: It can be concluded that bortezomib-based therapies are a potentially effective and well-tolerated option for desensitization and treatment of antibody-mediated rejection in kidney transplant candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.